

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

oplication No.:

09/744,226

Filed:

January 22, 2001

1st Inventor:

O. OHARA

For:

Novel G Protein Coupled Receptor and its DNA

Atty. Dkt. No.

2534 US0P

Art Unit:

1646

Examiner:

tba

Allowed:

Batch:

Paper No.:

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

RECEIVED

APR 0 3 2002

TECH CENTER 1600/2900

Sir:

Applicants request that a corrected Filing Receipt be issued for the above-identified case correcting the title of the invention. Please rewrite the title of the invention to read as follows:

--NOVEL G PROTEIN COUPLED RECEPTOR AND ITS DNA--

A copy of the Filing Receipt is enclosed showing the correction.

If there are any questions, please call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: February 20, 2002

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

LINCOLNSHIRE, IL 60069

FILING DATE 01/22/2001 GRP ART UNIT 1646

FIL FEE REC'D 1184

2534USOP

ATTY.DOCKET.NO DRAWINGS 25

TOT CLAIMS

IND CLAIMS

23115 TAKEDA PHARMACEUTICALS NORTH AMERICA, INC INTELLECTUAL PROPERTY DEPARTMENT 475 HALF DAY ROAD SUITE 500

CONFIRMATION NO. 5358 FILING RECEIPT

OC000000007324258

Date Mailed: 01/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Osamu Ohara, Chiba, JAPAN; Takahiro Nagase, Chiba, JAPAN; Nobuo Nomura, Chiba, JAPAN; Shuji Hinuma, Ibaraki, JAPAN; Ryo Fujii, Ibaraki, JAPAN; Osamu Kitahara, Ibaraki, JAPAN; Shinichi Mogi, Ibaraki, JAPAN;

RECEIVED

APR 0 3 2002

TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/03909 07/22/1999


Foreign Applications

JAPAN 10/207579 07/23/1998 JAPAN 10/225060 08/07/1998 JAPAN 10/284328 06/10/1998

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No



Novel g protein-conjugated receptor protein and dna thereof -Novel G. Protein Coupled Receptor and its DNA-

RECEIVED

APR 0 3 2002

TECH CENTER 1600/2900

530

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (i)); the Office of Foreign Assets Control. Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FEB 2 0 2002 85

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

09/744,226

Filed:

January 22, 2001

1st Inventor:

O. OHARA

For:

Novel G Protein Coupled Receptor and its DNA

Atty. Dkt. No.

2534 US0P

Art Unit:

1646

tba

Examiner:

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 916493047 US

DATE IN: February 20, 2002

RECEIVED

APR 0 3 2002

Itemized Papers/Items:

TECH CENTER 1600/2900

- 1. This certificate and a Return Receipt Postcard (2 pgs.)
- 2. Transmittal Form (1 pg. X 2)
- 3. Request to Correct Filing Receipt, and copy of Filing Receipt (3 pgs.)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231.

on this date, 2/20/02

Dated: 2/20/02

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA

PE						
0 2007 Blacco truco o olun cico	(+) incide this how	→ □				
Please type a plus sign MAB ander the Paperwork Reduction Act	of 1995, no person	s are required to re	A U.S. Patent and Tr espond to a collection of info	Approved for rademark Of ormation unl	use through 10/3 ffice: U.S. DEPAF less it displays a v	PTO/SB/21 (08-00 31/2002. OMB 0651-0031 RTMENT OF COMMERCE valid OMB control number
TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Application Number		/744,226	
			Filing Date	Ja	nuary 22,	2001
			First Named Invent	tor O.	OHARA	RECE
			Group Art Unit	16	646	APR 0 3
			Examiner Name	tba	a '	TECH CENTER:
Total Number of Pages in This Submi		ission 7	sion 7 Attorney Docket Number		10504	
		ENCL	OSURES (che	eck all ti	hat apply)	
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Assignment Papers (for an Application) Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks The Commissione charge any addition		Re Ce Re + c ioner is iditional	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Return Postcard. Certificate of Express Mailing Request to Correct Filing Receipt + copy of Filing Receipt er is hereby authorized to onal fees which may be any overpayment to	
Individual name	· ·		eg. No. 37,293	OR AGE	NT	
Signature	2//	46	1	•		
Date 2/20/02						
	7		ATE OF MAILING			
I hereby certify that this corresponding in an envelope addressed to	ondence is being o: Commissioner	deposited with the for Patents, Wa	ne United States Postal shington, DC 20231 on t	Service wi this date:	th sufficient pos	stage as first class
Typed or printed name	Gail L. Wi		 		, .	
Signature	duil	L. Win	noku	Date	2/20/0	20

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

When the second of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.